Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spirit Airlines Inc SAVEQ

Spirit Airlines, Inc. offers affordable travel to value-conscious guests (Guests). The Company’s all-Airbus fleet is one of the most fuel efficient in the United States. It serves approximately 93 destinations in 15 countries throughout the United States, Latin America and the Caribbean. Its ultra low-cost carrier (ULCC) business model allows it to compete principally by offering Guests unbundled base fares that remove components traditionally included in the price of an airline ticket. It provides customizable travel options starting with an unbundled fare. This allows its Guests to pay only for the options they choose like bags, seat assignments, refreshments and Wi-Fi - something the Company call A La Smarte. The Company operate the Spirit Saver$ Club, which is a subscription-based loyalty program that allows members access to unpublished, extra-low fares as well as discounted prices on bags and seats, shortcut boarding and security. It also operates the Free Spirit loyalty program.


OTCPK:SAVEQ - Post by User

Post by RomaJoyon Jun 03, 2022 3:55am
144 Views
Post# 34728664

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance


FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>